Motilent raises £1.2M to rollout its CE-marked GIQuant software — TFN

Motilent, a UK-based company using AI to assess digestive diseases, has secured £1.2 million in funding from the National Institute for Health and Care Research (NIHR). This investment will be used to roll out Motilent's CE-marked GIQuant software to over 10 NHS hospitals, focusing on Inflammatory Bowel Disease (IBD) and Crohn's Disease.  The funding will support a retrospective study on historic MRI scans and a prospective component involving over 3400 patients.

Motilent Secures £1.2 Million to Expand AI-Powered Digestive Disease Assessment

Motilent is a UK-based company specializing in the assessment of digestive diseases using AI medical image analysis. Their flagship product, GIQuant, is a CE-marked software designed to analyze MRI scans for Crohn's disease activity and predict treatment response.

A UK-based company specializing in AI-powered medical image analysis for digestive diseases.

3 years ago

Motilent Secures £1.2 Million to Expand AI-Powered Digestive Disease Assessment

Covered on